FDA Lupus Trial Design Guidance Will Go To Advisory Committee In Fall
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA is planning to present its draft guidance on lupus clinical trial design at a meeting of the Arthritis Advisory Committee this fall.
You may also be interested in...
La Jolla Riquent NDA Planned For Year-End; Will Seek Accelerated Approval
La Jolla Pharmaceuticals will pursue accelerated approval for its systemic lupus erythematosus agent Riquent (formerly LJP 394).
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011